Literature DB >> 30373394

State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.

Lara A Ray1,2, Spencer Bujarski1, Erica Grodin1, Emily Hartwell1, ReJoyce Green1, Alexandra Venegas1, Aaron C Lim1, Artha Gillis2, Karen Miotto2.   

Abstract

BACKGROUND: Alcohol use disorder (AUD) and its associated consequences remain significant public health concerns. Given that AUD represents a spectrum of severity, treatment options represent a continuum of care, ranging from single-session brief interventions to more intensive, prolonged, and specialized treatment modalities.
OBJECTIVE: This qualitative literature review seeks to describe the best practices for AUD by placing a particular emphasis on identifying those practices which have received the most empirical support.
METHOD: This review summarizes psychological and pharmacological intervention options for AUD treatment, with a focus on the relapse prevention phase of recovery. Psychological and pharmacological treatments are summarized in terms of the empirical evidence favoring each approach and the level of AUD severity for which they are most indicated. SCIENTIFIC SIGNIFICANCE: One of the broad assertions from this review is that while AUD is highly prevalent, seeking treatment for AUD is not. There are a myriad of behavioral and pharmacological treatments that have shown compelling evidence of efficacy for the treatment of AUD. In the behavioral treatment literature, cognitive behavioral therapy has received the most consistent support. Opioid antagonism (via naltrexone) has been the most widely studied pharmacotherapy and has produced moderate effect sizes. While none of the treatments reviewed herein represents a so-called silver bullet for AUD, they each have the potential to significantly improve the odds of recovery. Precision medicine, or the identification of best treatment matches for individual patients, looms as an important overarching goal for the field, although specific matches are not yet sufficiently reliable in their empirical evidence to warrant clinical dissemination.

Entities:  

Keywords:  AUD treatment; Alcohol use disorder; evidence-based treatment; psychopharmacology; psychosocial treatment

Mesh:

Substances:

Year:  2018        PMID: 30373394      PMCID: PMC6430676          DOI: 10.1080/00952990.2018.1528265

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  169 in total

Review 1.  The mechanisms of action of gabapentin and pregabalin.

Authors:  Graeme J Sills
Journal:  Curr Opin Pharmacol       Date:  2005-12-22       Impact factor: 5.547

Review 2.  The effectiveness of web-based interventions designed to decrease alcohol consumption--a systematic review.

Authors:  Bridgette M Bewick; Karen Trusler; Michael Barkham; Andrew J Hill; Jane Cahill; Brendan Mulhern
Journal:  Prev Med       Date:  2008-01-26       Impact factor: 4.018

3.  Project MATCH secondary a priori hypotheses. Project MATCH Research Group.

Authors: 
Journal:  Addiction       Date:  1997-12       Impact factor: 6.526

4.  Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?

Authors:  Lara A Ray; Spencer Bujarski; Megan M Yardley; Daniel J O Roche; Emily E Hartwell
Journal:  Am J Drug Alcohol Abuse       Date:  2017-04-20       Impact factor: 3.829

Review 5.  Computer and mobile technology-based interventions for substance use disorders: an organizing framework.

Authors:  Erika B Litvin; Ana M Abrantes; Richard A Brown
Journal:  Addict Behav       Date:  2012-09-11       Impact factor: 3.913

6.  Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.

Authors:  Karl Mann; Corey R Roos; Sabine Hoffmann; Helmut Nakovics; Tagrid Leménager; Andreas Heinz; Katie Witkiewitz
Journal:  Neuropsychopharmacology       Date:  2017-11-20       Impact factor: 7.853

7.  Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials.

Authors:  Molly Magill; Lara A Ray
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

8.  Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.

Authors:  Susanne Rösner; Stefan Leucht; Philippe Lehert; Michael Soyka
Journal:  J Psychopharmacol       Date:  2008-01       Impact factor: 4.153

9.  Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial.

Authors:  Sarah Bowen; Katie Witkiewitz; Seema L Clifasefi; Joel Grow; Neharika Chawla; Sharon H Hsu; Haley A Carroll; Erin Harrop; Susan E Collins; M Kathleen Lustyk; Mary E Larimer
Journal:  JAMA Psychiatry       Date:  2014-05       Impact factor: 21.596

10.  Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.

Authors:  Fernando A Furieri; Ester M Nakamura-Palacios
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

View more
  27 in total

Review 1.  Technology-Delivered Cognitive-Behavioral Interventions for Alcohol Use: A Meta-Analysis.

Authors:  Brian D Kiluk; Lara A Ray; Justin Walthers; Michael Bernstein; Jeffery S Tonigan; Molly Magill
Journal:  Alcohol Clin Exp Res       Date:  2019-09-30       Impact factor: 3.455

2.  Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.

Authors:  Aaron C Lim; Erica N Grodin; Rejoyce Green; Alexandra Venegas; Lindsay R Meredith; Kelly E Courtney; Nathasha R Moallem; Philip Sayegh; Edythe D London; Lara A Ray
Journal:  Am J Drug Alcohol Abuse       Date:  2020-04-28       Impact factor: 3.829

Review 3.  Prevention, screening, and treatment for heavy drinking and alcohol use disorder.

Authors:  Justin Knox; Deborah S Hasin; Farren R R Larson; Henry R Kranzler
Journal:  Lancet Psychiatry       Date:  2019-10-17       Impact factor: 27.083

4.  Neurocognitive performance in alcohol use disorder using the NIH toolbox: Role of severity and sex differences.

Authors:  Lindsay R Meredith; Aaron C Lim; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2020-08-29       Impact factor: 4.492

5.  Remission From Unhealthy Drinking Among Patients With an Alcohol Use Disorder: A Longitudinal Study Using Systematic, Primary Care-Based Alcohol Screening Data.

Authors:  Vanessa A Palzes; Andrea H Kline-Simon; Derek D Satre; Stacy Sterling; Constance Weisner; Felicia W Chi
Journal:  J Stud Alcohol Drugs       Date:  2020-07       Impact factor: 2.582

6.  Estimating Long-Term Drinking Patterns for People with Lifetime Alcohol Use Disorder.

Authors:  Carolina Barbosa; William N Dowd; Arnie P Aldridge; Christine Timko; Gary A Zarkin
Journal:  Med Decis Making       Date:  2019-10-03       Impact factor: 2.583

Review 7.  The Use of Functional Magnetic Resonance Imaging to Test Pharmacotherapies for Alcohol Use Disorder: A Systematic Review.

Authors:  Erica N Grodin; Lara A Ray
Journal:  Alcohol Clin Exp Res       Date:  2019-08-23       Impact factor: 3.455

8.  Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis.

Authors:  Shari Rogal; Ada Youk; Hongwei Zhang; Walid F Gellad; Michael J Fine; Chester B Good; Maggie Chartier; Andrea DiMartini; Timothy Morgan; Ramon Bataller; Kevin L Kraemer
Journal:  Hepatology       Date:  2020-05-22       Impact factor: 17.425

Review 9.  Behavioral Treatment for Patients With Alcohol-Related Liver Disease: A Primer for Hepatologists.

Authors:  Peng-Sheng Ting; Jason Wheatley; Po-Hung Chen
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-02-25

Review 10.  Mechanisms of Alcohol Addiction: Bridging Human and Animal Studies.

Authors:  John Kramer; Danielle M Dick; Andrea King; Lara A Ray; Kenneth J Sher; Ashley Vena; Leandro F Vendruscolo; Laura Acion
Journal:  Alcohol Alcohol       Date:  2020-10-20       Impact factor: 2.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.